A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Ustekinumab in Adult Japanese Subjects With Severe Atopic Dermatitis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Ustekinumab in Adult Japanese Subjects With Severe Atopic Dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK
  • Most Recent Events

    • 24 Mar 2017 Primary endpoint (Percent change from Baseline to Week 12 in the Eczema Area and Severity Index (EASI) score) has not been met,according to the results published in the British Journal of Dermatology.
    • 24 Mar 2017 Results published in the British Journal of Dermatology
    • 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top